These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36714014)

  • 21. Investigation on the interaction mechanism of different SARS-CoV-2 spike variants with hACE2: insights from molecular dynamics simulations.
    Wu J; Zhang HX; Zhang J
    Phys Chem Chem Phys; 2023 Jan; 25(3):2304-2319. PubMed ID: 36597957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Computational prediction of the effect of mutations in the receptor-binding domain on the interaction between SARS-CoV-2 and human ACE2.
    Celik I; Khan A; Dwivany FM; Fatimawali ; Wei DQ; Tallei TE
    Mol Divers; 2022 Dec; 26(6):3309-3324. PubMed ID: 35138508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anisotine and amarogentin as promising inhibitory candidates against SARS-CoV-2 proteins: a computational investigation.
    Kar P; Kumar V; Vellingiri B; Sen A; Jaishee N; Anandraj A; Malhotra H; Bhattacharyya S; Mukhopadhyay S; Kinoshita M; Govindasamy V; Roy A; Naidoo D; Subramaniam MD
    J Biomol Struct Dyn; 2022 Jul; 40(10):4532-4542. PubMed ID: 33305988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
    Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
    Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Computational insights into binding mechanism of drugs as potential inhibitors against SARS-CoV-2 targets.
    Arooj M; Shehadi I; Nassab CN; Mohamed AA
    Chem Zvesti; 2022; 76(1):111-121. PubMed ID: 34483461
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Huang X; Pearce R; Zhang Y
    Aging (Albany NY); 2020 Jun; 12(12):11263-11276. PubMed ID: 32544884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic virtual screening in search of SARS CoV-2 inhibitors against spike glycoprotein: pharmacophore screening, molecular docking, ADMET analysis and MD simulations.
    Dhameliya TM; Nagar PR; Gajjar ND
    Mol Divers; 2022 Oct; 26(5):2775-2792. PubMed ID: 35132518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. State-of-the-art Tools to Elucidate the Therapeutic Potential of TAT-peptide (TP) Conjugated Repurposing Drug Against SARS-CoV-2 Spike Glycoproteins.
    Ansari MA; Alomary MN; Jamal QMS; Almoshari Y; Salawi A; Almahmoud SA; Khan J
    Curr Pharm Des; 2022; 28(46):3706-3719. PubMed ID: 36278465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repurposing fusion inhibitor peptide against SARS-CoV-2.
    Efaz FM; Islam S; Talukder SA; Akter S; Tashrif MZ; Ali MA; Sufian MA; Parves MR; Islam MJ; Halim MA
    J Comput Chem; 2021 Dec; 42(32):2283-2293. PubMed ID: 34591335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of natural peptides from "PlantPepDB" database as anti-SARS-CoV-2 agents: A protein-protein docking approach.
    Bhandu P; Verma H; Raju B; Narendra G; Choudhary S; Singh M; Singh PK; Silakari O
    Phytomed Plus; 2023 May; 3(2):100446. PubMed ID: 37033295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of multiple SARS-CoV-2 proteins by an antiviral biomolecule, seselin from
    Nivetha R; Bhuvaragavan S; Muthu Kumar T; Ramanathan K; Janarthanan S
    J Biomol Struct Dyn; 2022; 40(21):11070-11081. PubMed ID: 34431451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 variants infectivity prediction and therapeutic peptide design using computational approaches.
    Abhinand CS; Prabhakaran AA; Krishnamurthy A; Raju R; Keshava Prasad TS; Nair AS; Rajasekharan KN; Oommen OV; Sudhakaran PR
    J Biomol Struct Dyn; 2023 Dec; 41(20):11166-11177. PubMed ID: 36572420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of tannic acid against SARS-cov-2 cell entry by targeting the interface region between S-protein-RBD and human ACE2.
    Chen X; Wang Z; Wang J; Yao Y; Wang Q; Huang J; Xiang X; Zhou Y; Xue Y; Li Y; Gao X; Wang L; Chu M; Wang Y
    Front Pharmacol; 2022; 13():940628. PubMed ID: 36003511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of nut protein-derived peptides against SARS-CoV-2 spike protein and main protease.
    Zhao W; Xu G; Yu Z; Li J; Liu J
    Comput Biol Med; 2021 Nov; 138():104937. PubMed ID: 34655899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-Silico Design of a Novel Tridecapeptide Targeting Spike Protein of SARS-CoV-2 Variants of Concern.
    Rajpoot S; Solanki K; Kumar A; Zhang KYJ; Pullamsetti SS; Savai R; Faisal SM; Pan Q; Baig MS
    Int J Pept Res Ther; 2022; 28(1):28. PubMed ID: 34924897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
    Fantini J; Chahinian H; Yahi N
    Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathway enrichment analysis of virus-host interactome and prioritization of novel compounds targeting the spike glycoprotein receptor binding domain-human angiotensin-converting enzyme 2 interface to combat SARS-CoV-2.
    Gollapalli P; B S S; Rimac H; Patil P; Nalilu SK; Kandagalla S; Shetty P
    J Biomol Struct Dyn; 2022 Apr; 40(6):2701-2714. PubMed ID: 33146070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
    Shahbazi B; Mafakher L; Teimoori-Toolabi L
    J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A computational study on active constituents of
    Shamsi S; Anjum H; Shahbaaz M; Khan MS; Ataya FS; Alamri A; Alhumaydhi FA; Husain FM; Rehman MT; Mohammad T; Islam A; Anjum F; Shamsi A
    J Biomol Struct Dyn; 2022 Oct; 40(17):7702-7713. PubMed ID: 33759703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.